PMID- 37130017
OWN - NLM
STAT- MEDLINE
DCOM- 20230720
LR  - 20240324
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 142
IP  - 2
DP  - 2023 Jul 13
TI  - Pembrolizumab in relapsed or refractory primary mediastinal large B-cell 
      lymphoma: final analysis of KEYNOTE-170.
PG  - 141-145
LID - 10.1182/blood.2022019340 [doi]
AB  - Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated 
      effective antitumor activity and acceptable safety of pembrolizumab 200 mg given 
      every 3 weeks for up to 35 cycles ( approximately 2 years) in patients with relapsed/refractory 
      (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after 
      or who were ineligible for autologous stem cell transplantation. The end points 
      included objective response rate (ORR), progression-free survival (PFS), and 
      duration of response (DOR) according to the investigator per 2007 Response 
      Criteria; overall survival (OS); and safety. In this final analysis, median 
      duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% 
      (complete response, 20.8%; partial response, 20.8%). The median DOR was not 
      reached; no patients who achieved a complete response progressed at the data 
      cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median 
      OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients 
      (56.6%) had any-grade treatment-related adverse events (AEs); the most common 
      were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs 
      occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of 
      follow-up, pembrolizumab continued to provide durable responses, with promising 
      trends for long-term survival and acceptable safety in R/R PMBCL.
CI  - (c) 2023 by The American Society of Hematology. Licensed under Creative Commons 
      Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), 
      permitting only noncommercial, nonderivative use with attribution. All other 
      rights reserved.
FAU - Zinzani, Pier Luigi
AU  - Zinzani PL
AUID- ORCID: 0000-0002-2112-2651
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 
      "Seragnoli," Bologna, Italy.
AD  - Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna, 
      Italy.
FAU - Thieblemont, Catherine
AU  - Thieblemont C
AD  - Department of Hemato-Oncology, Hopital Saint-Louis APHP, Paris, France.
FAU - Melnichenko, Vladimir
AU  - Melnichenko V
AD  - Department of Medical Oncology, Pirogov National Medical Surgical Center, Moscow, 
      Russia.
FAU - Bouabdallah, Krimo
AU  - Bouabdallah K
AD  - Department of Hematology and Cellular Therapy, University Hospital, Bordeaux, 
      France.
FAU - Walewski, Jan
AU  - Walewski J
AUID- ORCID: 0000-0003-4247-2674
AD  - Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research 
      Institute of Oncology, European Reference Network, Warsaw, Poland.
FAU - Majlis, Alejandro
AU  - Majlis A
AD  - Department of Hemato-Oncology, Clinica Alemana de Santiago, Santiago, Chile.
FAU - Fogliatto, Laura
AU  - Fogliatto L
AD  - Department of Clinical Hematology, Hospital de Clinicas de Porto Alegre, Porto 
      Alegre, Brazil.
FAU - Garcia-Sancho, A Martin
AU  - Garcia-Sancho AM
AUID- ORCID: 0000-0001-6330-1028
AD  - Department of Hematology, Hospital Universitario de Salamanca, Institute of 
      Biomedical Research of Salamanca, Centro de Investigacion Biomedica en Red 
      Cancer, Salamanca, Spain.
FAU - Christian, Beth
AU  - Christian B
AD  - Division of Hematology, The James Cancer Hospital and Solove Research Institute, 
      The Ohio State University, Columbus, OH.
FAU - Gulbas, Zafer
AU  - Gulbas Z
AD  - Department of Hematologic Oncology, Anadolu Medical Center, Gebze, Turkey.
FAU - Ozcan, Muhit
AU  - Ozcan M
AUID- ORCID: 0000-0002-1326-1918
AD  - Department of Hematology and Bone Marrow Transplantation Unit, Ankara University 
      School of Medicine, Ankara, Turkey.
FAU - Perini, Guilherme Fleury
AU  - Perini GF
AD  - Department of Hematology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Ghesquieres, Herve
AU  - Ghesquieres H
AD  - Department of Clinical Hematology, Lyon-Sud Hospital Center, Lyon, France.
FAU - Shipp, Margaret A
AU  - Shipp MA
AUID- ORCID: 0000-0002-3949-6897
AD  - Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA.
FAU - Thompson, Seth
AU  - Thompson S
AD  - Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.
FAU - Chakraborty, Samhita
AU  - Chakraborty S
AD  - Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.
FAU - Marinello, Patricia
AU  - Marinello P
AD  - Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ.
FAU - Armand, Philippe
AU  - Armand P
AD  - Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
CIN - Blood. 2023 Jul 13;142(2):121-122. PMID: 37440266
MH  - Adult
MH  - Humans
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Mediastinal Neoplasms/drug therapy
MH  - *Thymus Neoplasms
MH  - Transplantation, Autologous
PMC - PMC10651864
COIS- Conflict-of-interest disclosure: P.L.Z. reports advisory/consultancy roles with 
      Secura Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG 
      Therapeutics, Takeda, Roche, EUSA Pharma, Kyowa Kirin, Novartis, ADC 
      Therapeutics, Incyte, and BeiGene; and speaker bureau roles with Celltrion, 
      Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, EUSA 
      Pharma, Kyowa Kirin, Novartis, Incyte, and BeiGene. C.T. reports 
      advisory/consultancy roles and travel accommodations/expenses with Roche, Incyte, 
      Novartis, Kite/Gilead, Amgen, Takeda, and BMS. K.B. reports honoraria from 
      Takeda, Kite-Gilead, Sandoz, and AbbVie; advisory/consultancy roles with Takeda 
      and Kite-Gilead; and research funding from AbbVie and Takeda. J.W. reports 
      advisory/consultancy roles with Novartis; and research grant/funding from 
      AstraZeneca, BMS Celgene, Epizyme, Gilead, GSK, Incyte, Janssen-Cilag, 
      Karyopharm, Morphosys, MSD, Nanovector, Polish Lymphoma Research Group, Polish 
      Myeloma Consortium, Regeneron, Roche, Seagen, Takeda, and TG Therapeutics. L.F. 
      reports honoraria from AstraZeneca. A.M.G.-S. reports honoraria from Roche, 
      BMS/Celgene, Janssen, Servier, Gilead/Kite, Takeda, EUSA Pharma, and Novartis; 
      advisory/consultancy roles with Roche, BMS/Celgene, Kyowa Kirin, Clinigen, EUSA 
      Pharma, Novartis, Gilead/Kite, Servier, Incyte, Lilly, Takeda, ADC Therapeutics 
      America, and Miltenyi; research grant/funding from Janssen and Teva; and 
      travel/accommodation/expenses from Gilead/Kite, Janssen, Roche, BMS/Celgene, 
      Servier, and Kern Pharma. B.C. reports advisory/consultancy roles with Genentech, 
      MorphoSys, ADC Therapeutics, and GenMab; and research grant/funding from 
      Genentech/Roche, Celgene/BMS, Acerta, Triphase, MorphoSys, SeaGen, and 
      Millennium. Z.G. reports an advisory/consultancy role paid to the institution 
      with BMS and a speaker bureau role paid to the institution with Amgen. M.O. 
      reports research grant/funding from AbbVie, Bayer, Janssen, Acerta, Reddy's, MSD, 
      Roche, and Takeda and travel/accommodation/expenses from AbbVie, Jazz, and Roche. 
      G.F.P. reports advisory/consultancy roles with Janssen, AbbVie, Takeda, and 
      AstraZeneca; speaker bureau roles with Janssen, AbbVie, Takeda, AstraZeneca, and 
      MSD; and travel/accommodation/expenses from Janssen, Takeda, AstraZeneca, and 
      MSD. H.G. reports honoraria from Gilead, Roche, BMS, and AbbVie and 
      advisory/consultancy roles with Gilead and Roche. M.A.S. reports research 
      grant/funding from AstraZeneca, Bayer, BMS, and AbbVie. S.T. reports employment 
      at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, and is a 
      share/stockholder or has stock options in Merck & Co, Inc, Rahway, NJ. S.C. 
      reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, 
      Rahway, NJ, and is a share/stockholder or has stock options in Merck & Co, Inc, 
      Rahway, NJ. P.M. reports employment at Merck Sharp & Dohme LLC, a subsidiary of 
      Merck & Co, Inc, Rahway, NJ, and is a share/stockholder or has stock options in 
      Merck & Co, Inc, Rahway, NJ. P.A. reports advisory/consultancy roles with Merck, 
      BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, 
      Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, 
      AstraZeneca, Genentech, and Xencor and research grant/funding from Merck, BMS, 
      Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM, and Kite. The 
      remaining authors declare no competing financial interests.
EDAT- 2023/05/02 18:42
MHDA- 2023/07/17 06:42
PMCR- 2023/05/10
CRDT- 2023/05/02 12:33
PHST- 2023/04/10 00:00 [accepted]
PHST- 2022/12/07 00:00 [received]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/05/02 18:42 [pubmed]
PHST- 2023/05/02 12:33 [entrez]
PHST- 2023/05/10 00:00 [pmc-release]
AID - S0006-4971(23)01037-6 [pii]
AID - 10.1182/blood.2022019340 [doi]
PST - ppublish
SO  - Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340.